Dr. Christine Hughes
3-202 Edmonton Clinic Health Academy
University of Alberta
11405 - 87 Ave.
Edmonton, AB, T6G 1C9
(780) 492 - 5903
Associate Professor & Chair, Pharmacy Practice Division
1997, Doctor of Pharmacy, University of British Columbia, Vancouver, British Columbia.
1994, Bachelor of Science in Pharmacy, University of Alberta, Edmonton, Alberta.
Alberta College of Pharmacists - Additional Prescribing Authority and Authorization to Administer
drugs by Injection
Pharmacy Examining Board of Canada
1. Pharmacists Association of Alberta
2. Canadian Pharmacist Association
3. Canadian Society of Hospital Pharmacists
4. Canadian College of Clinical Pharmacy
5. Association of Faculties of Pharmacy of Canada
6. Canadian HIV/AIDS Pharmacists Network
My current practice/research specialization is in the area of HIV/AIDS. I currently hold a cross-appointment with the Alberta Health Services as a clinical pharmacotherapy Practitioner with the Northern Alberta HIV Program.
Areas of Research
My research interests include adherence to antiretroviral drugs, as well as the safety and effectiveness of antiretroviral therapy in practice. In addition, I am interested in the uptake of expanded scopes of pharmacy practice.
1. Wong K, Hughes C, Plitt S, Foisy M, MacDonald J, Johnson M, Singh A. HIV Non-occupational Post-
exposure Prophylaxis in a Canadian province: Treatment Completion and Follow-up Testing. International
Journal of STD & AIDS 2010;21:617-21.
2. Hughes CA, Foisy M, Tseng A. Interactions between antifungals and antiretroviral agents. Expert Opin
Drug Saf 2010;9:1-20.
3. Hughes CA, Schindel T. Evaluation of a professional development course on laboratory values: can
practice change? Int J Pharm Pract 2010;18(3):174-9.
4. Hills-Nieminen C, Hughes CA, Houston S, Shafran SD. Drug-drug interaction between itraconazole and
protease inhibitor lopinavir/ritonavir. Ann Pharmacother 2009;43:2117-20.
5. Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: a review of the efficacy, safety,
pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and
raltegravir. Expert Opin Pharmacother 2009;10(15):2445-66.
6. Zuk D, Hughes CA, Foisy M, Robinson J, Singh A, Houston S. Adverse Effects of Antiretrovirals in HIV-
infected Pregnant Women. Ann Pharmacother 2009;43:1028-35.
7. Yuksel N, Hughes C. Is a 1-year residency program long enough to prepare hospital pharmacists for
practice? The “con” side. Can J Hosp Pharm 2009; 62(1): 44-5.
8. Hughes CA, Zuk D, Foisy M, Robinson J, Singh A, Houston S. Prenatal Screening and Perinatal HIV
transmission in northern Alberta: 1999-2006. Am J Public Health, 2009;99:S412-S416.
9. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions.
Ann Pharmacother 2008;42:1048-59.
10. Yakiwchuk EM, Foisy M, Hughes C. Complexity of drug interactions between voriconazole and
antiretroviral agents. Ann Pharmacother 2008;42:698-703.
11. Hughes CA, Foisy M, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE. Abacavir hypersensitivity
reaction: update on management and prevention. Ann Pharmacother 2008;387-96.